Diagnostic value of circulating chromogranin a for neuroendocrine tumors: A systematic review and meta-analysis

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Yang, Xin ^a   Yang, Yuan ^a   Li, Zhilu ^a   Cheng, Chen ^a   Yang, Ting ^a   Wang, Cheng ^a   Liu, Lin ^a   Liu, Shengchun ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; TUMOR MARKER;

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HUMAN; NEUROENDOCRINE TUMOR; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUMOR DIAGNOSIS; BLOOD; META ANALYSIS; NEUROENDOCRINE TUMORS;

CHROMOGRANIN A; HUMANS; NEUROENDOCRINE TUMORS;

EID: 84929456662     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124884     Document Type: Article

References (57)

1. Solcia E., kloppel G., Sobin L.H.. World Health Organization International Histological Classification of Tumours: Histological Typing of Endocrine Tumours: Second Edition. Clinical Endocrinology 2000; 53:259-259.
2. Langley K. The neuroendocrine concept today. Annals of the New York Academy of Sciences 1994; 733:1-17. PMID: 7978857.
3. Hauser H, Wolf G, Uranus S, Klimpfinger M. Neuroendocrine tumours in various organ systems in a ten-year period. European journal of surgical oncology: The journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1995; 21:297-300.
4. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine reviews 2004; 25:458-511. PMID: 15180952.
5. Neary PC, Redmond PH, Houghton T, Watson GR, Bouchier-Hayes D. Carcinoid disease: review of the literature. Diseases of the colon and rectum 1997; 40:349-362. PMID: 9118753.
6. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2008; 26:3063-3072.
7. Kulke MH, Benson AB 3rd, Bergsland E, et al. Neuroendocrine tumors. Journal of the National Comprehensive Cancer Network: JNCCN 2012; 10:724-764. PMID: 22679117.
8. Vinik AI, Woltering EA, Warner RR, Caplin M, O'Doriso TM, Wiseman GA, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010; 39:713-734. doi:10.1097/MPA.0b013e3181ebaffd PMID: 20664471.
9. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. The Lancet Oncology 2008; 9:61-72. doi:10.1016/S1470-2045(07)70410-2 PMID: 18177818.
10. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128:1717-1751. PMID: 15887161.
11. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999; 86:858-865. PMID: 10463986.
12. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. The New England journal of medicine 2003; 348:1134-1149. PMID: 12646671.
13. Colombo B, Curnis F, Foglieni C, Monno A, Arrigoni G, Corti A. Chromogranin A expression in neoplastic cells affects tumor growth and morphogenesis in mouse models. Cancer research 2002; 62:941- 946. PMID: 11830555.
14. Colombo B, Longhi R, Marinzi C, Magni F, Cattaneo A, Yoo SH, et al. Cleavage of chromogranin A Nterminal domain by plasmin provides a new mechanism for regulating cell adhesion. The Journal of biological chemistry 2002; 277:45911-45919. PMID: 12297497.
15. Helle KB, Corti A, Metz-Boutigue MH, Tota B. The endocrine role for chromogranin A: A prohormone for peptides with regulatory properties. Cellular and molecular life sciences: CMLS 2007; 64:2863-2886. PMID: 17717629.
16. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. The Journal of clinical endocrinology and metabolism 1997; 82:2622-2628. PMID: 9253344.
17. Baudin E, Gigliotti A, Ducreux M, Ropers J, Comoy E, Sabourin JC, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. British journal of cancer 1998; 78:1102-1107. PMID: 9792158.
18. Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW. Chromogranin A: its clinical value as marker of neuroendocrine tumours. European journal of clinical investigation 1998; 28:431-440. PMID: 9693933.
19. Guignat L, Bidart JM, Nocera M, Comoy E, Schlumberger M, Baudin E. Chromogranin A and the alphasubunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma. British journal of cancer 2001; 84:808-812. PMID: 11259096.
20. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Annals of internal medicine 2011; 155:529-536. doi:10.7326/0003-4819-155-8-201110180-00009 PMID: 22007046.
21. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: A software for meta-analysis of test accuracy data. BMC medical research methodology 2006; 6:31. PMID: 16836745.
22. Tohmola N, Itkonen O, Sane T, Markkanen H, Joenvaara S, Renkonen R, et al. Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker. Clinica chimica acta; international journal of clinical chemistry 2014; 428:38-43. doi:10.1016/j.cca.2013.10.025 PMID: 24211728.
23. Modlin IM, Drozdov I, Kidd M. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PloS one 2013; 8:e63364. doi:10.1371/journal.pone.0063364 PMID: 23691035.
24. Korse CM, Taal BG, Vincent A, Van Velthuysen ML, Baas P, Buning-Kager JC, et al. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments. European journal of cancer (Oxford, England: 1990) 2012; 48:662-671. doi:10.1016/j.ejca.2011.08.012 PMID: 21945100.
25. Molina R, Alvarez E, Aniel-Quiroga A, Borque M, Candas B, Leon A, et al. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumour biology: The journal of the International Society for Oncodevelopmental Biology and Medicine 2011; 32:13-22. doi:10.1007/s13277-010-0085-x PMID: 20730520.
26. Donica H, Malecha-Jedraszek A, Stroslawska E, Burska A, Szubstarski F. Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis. Folia histochemica et cytobiologica/Polish Academy of Sciences, Polish Histochemical and Cytochemical Society 2010; 48:603- 610. doi:10.2478/v10042-010-0088-x PMID: 21478104.
27. Belli SH, Oneto A, Aranda C, O'Connor JM, Domenichini E, Roca E, et al. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: A multicenter study developed in Argentina. Acta gastroenterologica Latinoamericana 2009; 39:184-189. PMID: 19845257.
28. Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, et al. Chromogranin A as a marker of neuroendocrine neoplasia: An Italian Multicenter Study. Endocrine-related cancer 2007; 14:473-482. PMID: 17639060.
29. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2007; 25:1967-1973.
30. Panzuto F, Severi C, Cannizzaro R, Falconi M, Angeletti S, Pasquali A, et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. Journal of endocrinological investigation 2004; 27:6-11. PMID: 15053236.
31. Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, et al. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004; 60:644-652. PMID: 15104570.
32. Peracchi M, Conte D, Gebbia C, Penati C, Pizzinelli S, Arosio M, et al. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. European journal of endocrinology/European Federation of Endocrine Societies 2003; 148:39-43.
33. Bernini GP, Moretti A, Ferdeghini M, Ricci S, Letizia C, D'Erasmo E, et al. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours. British journal of cancer 2001; 84:636-642. PMID: 11237384.
34. Tomassetti P, Migliori M, Simoni P, Casadei R, De Iasio R, Corinaldesi R, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. European journal of gastroenterology & hepatology 2001; 13:55-58. doi:10.1007/s00535-009-0024-z PMID: 19308310.
35. Lijmer JG, Bossuyt PM, Heisterkamp SH. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Statistics in medicine 2002; 21:1525-1537. PMID: 12111918.
36. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. Journal of clinical epidemiology 2000; 53:1119-1129. PMID: 11106885.
37. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: A single indicator of test performance. Journal of clinical epidemiology 2003; 56:1129-1135. PMID: 14615004.
38. Jones CM, Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. The Annals of thoracic surgery 2005; 79:16-20. PMID: 15620907.
39. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-1101. PMID: 7786990.
40. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. Journal of clinical epidemiology 2005; 58:882-893. PMID: 16085191.
41. Modlin IM, Champaneria MC, Bornschein J, Kidd M. Evolution of the diffuse neuroendocrine system- clear cells and cloudy origins. Neuroendocrinology 2006; 84:69-82. PMID: 17106184.
42. Ameri P, Ferone D. Diffuse endocrine system, neuroendocrine tumors and immunity: what's new? Neuroendocrinology 2012; 95:267-276. doi:10.1159/000334612 PMID: 22248635.
43. Pearse AG. Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid and ultimobranchial C cells and calcitonin. Proceedings of the Royal Society of London Series B, Containing papers of a Biological character Royal Society (Great Britain) 1968; 170:71-80.
44. Pearse AG, Takor TT. Neuroendocrine embryology and the APUD concept. Clin Endocrinol (Oxf) 1976; 5 Suppl:229S-244S. PMID: 29734.
45. Lindblom A, Liljegren A. Regular review: Tumour markers in malignancies. BMJ (Clinical research ed) 2000; 320:424-427. PMID: 10669448.
46. O'Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. The New England journal of medicine 1984; 311:764-770. PMID: 6472366.
47. Sobol RE, O'Connor DT, Addison J, Suchocki K, Royston I, Deftos LJ. Elevated serum chromogranin A concentrations in small-cell lung carcinoma. Annals of internal medicine 1986; 105:698-700. PMID: 3021037.
48. Hsiao RJ, Seeger RC, Yu AL, O'Connor DT. Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. The Journal of clinical investigation 1990; 85:1555-1559. PMID: 2332506.
49. Blind E, Schmidt-Gayk H, Sinn HP, O'Connor DT, Raue F. Chromogranin A as tumor marker in medullary thyroid carcinoma. Thyroid: official journal of the American Thyroid Association 1992; 2:5-10. PMID: 1356053.
50. Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. The Journal of endocrinology 1995; 144:49-59. PMID: 7891024.
51. O'Connor DT, Burton D, Deftos LJ. Immunoreactive human chromogranin A in diverse polypeptide hormone producing human tumors and normal endocrine tissues. The Journal of clinical endocrinology and metabolism 1983; 57:1084-1086. PMID: 6352725.
52. O'Connor DT. Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. Regulatory peptides 1983; 6:263-280. PMID: 6622754.
53. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. The New England journal of medicine 1986; 314:1145-1151. PMID: 3007986.
54. Degg TJ, Allen KR, Barth JH. Measurement of plasma 5-hydroxyindoleacetic acid in carcinoid disease: An alternative to 24-h urine collections? Annals of clinical biochemistry 2000; 37 (Pt 5):724-726.
55. Kema IP, Schellings AM, Meiborg G, Hoppenbrouwers CJ, Muskiet FA. Influence of a serotonin- And dopamine-rich diet on platelet serotonin content and urinary excretion of biogenic amines and their metabolites. Clinical chemistry 1992; 38:1730-1736. PMID: 1382000.
56. O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical markers. Neuroendocrinology 2009; 90:194-202. doi:10.1159/000225948 PMID: 19713711.
57. Tapia FJ, Polak JM, Barbosa AJ, Bloom SR, Marangos PJ, Dermody C, et al. Neuron-specific enolase is produced by neuroendocrine tumours. Lancet 1981; 1:808-811. PMID: 6111674.